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Abstract: Imaging studies provide essential diagnostic information
in the care of cancer patients. Unfortunately, radiographic findings
are not always diagnostic and thus an alternative approach with
biomarkers has been suggested as part of the diagnostic evaluation.
This discussion focuses on integration of biomarkers with imaging
in the effort to guide patient management.
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The primary goal of radiographic evaluation is to providediagnostic information. Although imaging offers exquis-
ite anatomic, morphologic and, more recently with positron
emission tomography, biochemical and metabolic informa-
tion, the findings are not always sufficient to establish a
definitive diagnosis. Thus, interventional procedures are often
required for tissue sampling before treatment is initiated.
Even after a pathologic diagnosis is confirmed, characteriza-
tion of lesions is often inadequate, as therapeutic options and
prognosis are frequently based on sequential follow-up im-
aging studies.
As an alternative and complementary approach to im-
aging, biomarkers have been suggested as part of the diag-
nostic strategy.1,2 Biomarkers could theoretically provide the
necessary detail to address issues that conventional imaging
and pathologic evaluation have not been able to offer.
Discovery of Biomarkers
Biomarkers in medical practice have been defined as
indicators of normal biological processes, pathologic pro-
cesses, or response to a therapeutic intervention. They are
intended to substitute for a clinical endpoint and can be
expected to suggest a diagnosis, characterize a disease, pre-
dict responsiveness to treatment, or suggest outcome.2 Thus,
by definition, many imaging and specimen features can be
considered biomarkers, but there remain a number of unre-
solved issues because of the lack of sensitivity and specificity
of these findings. If biomarkers are to be effective in clinical
practice, they should be easily obtainable with noninvasive or
minimally invasive procedures, they should be accurate, and
the assay must be reproducible and cost effective.
The search for tumor biomarkers begins with an under-
standing that the fundamental property of cancer is that it is
a disease of the genes. Many investigators have explored a
variety of biological biomarkers, including DNA, mRNA,
and proteins, which can differentiate cancer from normal or
other diseases. Some have attempted to develop biomarkers
by elucidating the spectrum of genetic changes using gene or
oligonucleotide microarrays. Although this has resulted in a
large amount of data and the elucidation of links between
biological pathways involved in oncogenesis, integration of
this information for clinical purposes has been difficult to
achieve. This is not only because tumors are heterogeneous
but also because minimal genetic changes often have a large
spectrum of downstream consequences. It is often difficult to
sort out which are meaningful markers for clinical practice.
In addition, given the disparity between gene transcrip-
tion, protein expression, and posttranslational modifications,
it is possible that relevant phenotypic characteristics of dis-
ease may be overlooked by investigations of gene expression
or the transcriptome alone. Because of this, an interest in
directly studying disease-specific changes in protein expres-
sion is becoming an attractive alternative strategy. The ability
of proteomic analysis to complement transcript level–based
microarray studies has been well documented. It is postulated
that the phenotype of a cell is a reflection of its proteome.
Thus elucidation of comprehensive protein profiles will per-
mit investigators to gain more insight into tumor biology.3–5
Proteomic technology, however, is just beginning to be en-
gaged in translational applications, and more basic research
into protein separation, amplification, and differential expres-
sion would clearly lead to advances in protein biomarker
discovery.6
Clinical Utility of Biomarkers
Regardless of the platform or type of biomarkers dis-
covered, appropriate incorporation of tumor biomarkers into
clinical practice could dramatically alter diagnostic strategies,
affect treatment options, and eventually improve patient out-
comes.7 There are a number of specific management issues
that would undoubtedly benefit from more accurate lesion
characterization. A clear understanding of the relevant diag-
nostic problems and translation into clinical practice, how-
ever, is a complex process. Integration of biomarkers with
imaging requires knowledge of not only the specific clinical
question but the current limitations of radiologic studies. The
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most common challenges in tumor diagnostics can be divided
into four general categories. These include the following:
1. Defining a high-risk population.
2. Determining the cause of an indeterminate abnormality
identified on imaging studies and establishing a diag-
nosis (Figure 1).
3. Characterizing disease (prognostics/therapeutics).
4. Predict disease progression.
The first three issues help in the identification of pa-
tients with disease, diagnosis of disease, and characterization
of lesions so that appropriate treatment is administered, and
suggest outcomes. The last category, following disease pro-
gression, has traditionally been an essential element in patient
management, but one could argue that as tumor characteriza-
FIGURE 1. Two patients with indeterminate nodules. Both had their blood tested for biomarkers MUC1 and CK19 (epithelial
cell markers) to differentiate benign from malignant lesions. (A) A 68- year-old man underwent computed tomographic scan-
ning for emphysema. Axial computed tomographic image demonstrates an 8-mm left lower lobe nodule. Several other small
nodules were also identified. Follow-up radiographic studies over the next year showed these to be stable, suggestive of a be-
nign abnormality. The patient has had 2-year clinical follow-up and is without evidence of a malignancy. (B) Reverse-transcrip-
tase polymerase chain reaction was negative for both MUC1 and CK19, suggesting a benign lesion. Lanes: L, ladder; 1, CK19;
2, MUC1; 3, positive control; 4, negative control. Lane 3 was added to this image for direct comparison. (C) A 71-year-old
woman with an enlarging nodule on chest radiography. Axial computed tomographic image confirms the 1.5-cm nodule.
This proved to be non–small-cell lung cancer. (D) Reverse-transcriptase polymerase chain reaction was positive for both MUC1
and CK19, suggesting malignancy. Lanes: L, ladder; 1, CK19, 2. MUC1; 3, positive control; 4, negative control. Lane 3 was
added to this image for direct comparison.
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tion at the time of diagnosis becomes more sophisticated and
tailored therapy becomes a reality, the need to follow these
patients with anything more than a routine imaging study will
be unnecessary.
SUMMARY
Once diagnostic issues are defined and biomarkers
discovered, specific hypothesis-driven clinical trials can be
performed. As the field of molecular diagnostics evolves, it
will be essential to integrate a spectrum of noninvasive
techniques into the choice of diagnostic methods if improve-
ments in patient outcomes are to be realized.
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